Tigatuzumab

Tigatuzumab
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Tigatuzumab is a monoclonal antibody designed for the treatment of various types of cancer. It is specifically developed to target and bind to the death receptor 5 (DR5), a protein overexpressed in many types of cancer cells. By binding to DR5, tigatuzumab triggers a process known as apoptosis (programmed cell death) in the cancer cells, thereby inhibiting tumor growth.

Mechanism of Action

Tigatuzumab works by targeting the DR5 receptor on the surface of cancer cells. DR5 is a member of the tumor necrosis factor (TNF) receptor superfamily, which plays a crucial role in triggering apoptosis. The binding of tigatuzumab to DR5 activates the receptor's apoptotic signaling pathways, leading to the death of the cancer cell.

Clinical Trials

Tigatuzumab has been evaluated in various clinical trials for its effectiveness and safety in treating different types of cancers, including colorectal cancer, non-small cell lung cancer, and breast cancer. These studies assess the antibody's ability to improve survival rates and reduce tumor size as part of combination therapies or as a monotherapy.

Development and Approval

The development of tigatuzumab is part of a broader effort to harness the power of the immune system in fighting cancer. As of the last update, tigatuzumab is still undergoing clinical trials and has not yet received approval from regulatory bodies such as the Food and Drug Administration (FDA) for general medical use.

Potential and Challenges

While tigatuzumab shows promise in targeting and killing cancer cells, its development faces challenges typical of monoclonal antibody therapies, such as immune system reactions, high production costs, and the need for precise targeting to avoid affecting normal cells.

See Also

• Monoclonal antibodies
• Apoptosis
• Cancer treatment